



RESEARCH

Open Access

# Primary CD8<sup>+</sup> T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4<sup>+</sup> T cells

Robert W Buckheit III<sup>1</sup>, Robert F Siliciano<sup>1,2</sup> and Joel N Blankson<sup>1\*</sup>

## Abstract

**Background:** Elite controllers or suppressors have the remarkable capacity to maintain HIV-1 plasma RNA levels below the limit of detection of clinical assays (<50 copies/mL) without therapy and have a lower frequency of latently infected cells compared to chronic progressors. While it is unclear how this reduced seeding of the reservoir is achieved, it is possible that effective CTL responses play an important role in limiting the size of the latent reservoir.

**Results:** Herein, we demonstrate that primary CD8<sup>+</sup> T cells from HLA-B\*57/5801 elite suppressors were able to efficiently eliminate resting and activated primary CD4<sup>+</sup> T cells shortly after viral entry and prior to productive infection. CD8<sup>+</sup> T cells from elite suppressors were significantly more effective at eliminating these cells than CD8<sup>+</sup> T cells from chronic progressors.

**Conclusions:** Nonproductively infected CD4<sup>+</sup> T cells may represent a subpopulation of cells that are precursors to latently infected cells; therefore, the effective elimination of these cells may partially explain why elite suppressors have a much lower frequency of latently infected cells compared to chronic progressors. Thus, a vaccine strategy that elicits early and potent CD8<sup>+</sup> T cell responses may have the capacity to limit the seeding of the latent reservoir in HIV-1 infection.

**Keywords:** HIV-1 Latency, Elite Suppression, CD8 Elimination, Non-productive Infection

## Background

The development of a successful HIV-1 vaccine is paramount in combating the HIV-1 pandemic. In most patients, HIV-1 infection is characterized by high viral load and progressive CD4<sup>+</sup> T cell decline. In these patients, known as chronic progressors (CP), AIDS develops in an average of ten years in the absence of antiretroviral therapy. Elite controllers or suppressors (ES) are remarkable HIV-1-infected individuals who restrict viral replication to below the limit of detection of standard clinical assays (<50 of HIV-1 RNA copies/mL of plasma) and represent less than one percent of the HIV-1 infected population [1,2]. The mechanism of this control is still unclear. A better understanding of the mechanisms involved in this control could be useful in defining the characteristics of an effective HIV-1 vaccine.

A qualitatively superior CD8<sup>+</sup> T cell response has been most closely associated with control of viral replication. HLA-B\*57 is over represented in ES cohorts [3-9] and was identified as a major determinant of control in multiple genome wide association studies [10-15]. Additionally, the maintenance of a polyfunctional HIV-1-specific CD8<sup>+</sup> T cell response [16-18], as well as elevated proliferation and lytic granule loading have each been implicated in control of viral replication [3,19,20]. Unstimulated CD8<sup>+</sup> T cell from ES have also been shown suppress viral replication more effectively compared to than CP CD8<sup>+</sup> T cells [21,22]. Most convincingly, studies in the macaque model of elite suppression have shown that depletion of CD8<sup>+</sup> T cells with monoclonal antibodies results in a loss of viral control [23,24].

While maintaining similar levels of circulating viremia as antiretroviral treated patients [3,25-27], ES have a reduced number of latently infected cells compared to CP [5,28-30]. A sensitive co-culture assay [31] was used to show that the frequency of latently infected cells in the blood of ES

\* Correspondence: jblanks@jhmi.edu

<sup>1</sup>Department of Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, BRB 880, Baltimore, MD 21205, USA

Full list of author information is available at the end of the article

was 10 to 50 fold lower than the frequency observed for CPs who were on suppressive HAART regimens [29]. Additionally, ES have significantly lower levels of integrated proviral DNA compared to CP [28]. The lower levels of peak viremia during acute infection [32,33] that have been observed in some ES may partially explain the low frequency of latently infected cells in these patients. However, other mechanisms may contribute to this phenomenon. In a primary model system of latency, CD8<sup>+</sup> T cells from ES were observed to be more effective at targeting reactivated latently infected cell than CD8<sup>+</sup> T cells from individuals on suppressive HAART regimens [34]. Additionally, in a recent study in the SIV macaque model, a CMV based vaccine strategy was shown to provide impressive control of SIV replication in a subset of vaccinated animals. Interestingly, this control of viral replication was not abrogated when CD8<sup>+</sup> T cell were depleted using antibodies, and very few SIV infected CD4<sup>+</sup> T cells were seen at necropsy, suggesting that complete clearance of virus may have been achieved [35].

We hypothesized that ES CD8<sup>+</sup> T cells might be capable of eliminating infected CD4<sup>+</sup> T cells that are precursors of latently infected cells. Latency may be established when infected CD4<sup>+</sup> T lymphoblasts revert back to a resting state that is non-permissive for viral gene expression [36] or through direct infection of resting CD4<sup>+</sup> T cells [37]. In either case, the elimination of CD4<sup>+</sup> T cells immediately after infection and before any viral genes are expressed should help prevent the establishment of latency. This targeting of non-productively infected cells early after viral infection by CD8<sup>+</sup> T cell clones and cell lines has been documented in HIV and SIV infection models [38-40] however, it is unclear whether primary CD8<sup>+</sup> T cells from ES can mediate this type of response.

In this study, we use a CD8<sup>+</sup> T cell elimination assay with unstimulated, autologous CD4<sup>+</sup> T cell targets to demonstrate that CD8<sup>+</sup> T cells from HLA-B\*57<sup>+</sup> ES are able to eliminate non-productively infected resting and activated CD4<sup>+</sup> T cells. This response was significantly superior to the response observed in both HLA-B\*57/5801<sup>+</sup> and HLA-B\*57/5801<sup>-</sup> CPs. Therefore, a potent CD8<sup>+</sup> T cell response that targets non-productively infected cells in ES could contribute to the control of viral replication and may partially explain the reduced frequency of latently infected CD4<sup>+</sup> T cells.


## Results and discussion

To measure infection immediately after spinoculation, we infected CD4<sup>+</sup> T cells and stained with an antibody against the Gag p24 antigen. This allowed for detection of Gag stained cells shortly after infection, whereas GFP can only be reliably detected two to three days after infection. To observe the kinetics of infection, we analyzed infection in 3 healthy donors. We spinoculated primary

CD4<sup>+</sup> T cells with both an X4 and R5 pseudotyped virus, and treated the cells with an antibody specific for the CD4 receptor, 1.2 μM maraviroc (MVC), 25 nM ADM3100 (ADM) or 10 μM T20 during spinoculation. Gag staining was then performed immediately after spinoculation (hour 0). The CD4 antibody should block both X4 and R5 viruses from binding the primary receptor CD4, whereas MVC and ADC are specific antagonist of CCR5 and CXCR4 and should inhibit the infection of R5 and X4 viruses, respectively. Treatment with anti-CD4 antibody reduced infection at 0 hours post infection in for both R5 and X4 pseudotype viruses. MVC treatment specifically inhibited R5 virus infection (Figure 1A), whereas ADM specifically inhibited X4 virus infection (Figure 1B). Thus, the high level of Gag positivity seen immediately after spinoculation is mediated by virus binding that is CD4 and co-receptor specific. We also treated CD4<sup>+</sup> T cells with T20 during spinoculation and observed a reduction in the level of Gag positivity suggesting that viral fusion and entry occurs during this process (Figure 1A, B). However, this was an incomplete block suggesting that some of the Gag positivity observed immediately after spinoculation could represent virus that has bound the cell surface, but has yet to fuse with and enter the cell.

To characterize the kinetics of infection for the X4 pseudotype virus, we observed infection at 0, 6, and 18 hours post spinoculation. Infection remained relatively constant from hour 0 to hour 18, and T20, CD4, and ADC treatment maintained a reduction in the level of infection (Figure 1C). Additionally, spinoculation with X4 virus was performed at 4° Celsius and 25° Celsius and little Gag positivity was observed by FACS analysis at the lower temperature (Figure 1D). Thus, spinoculation is resulting in a high level of interaction between virion and target cells that is CD4 and co-receptor specific, and largely requires fusion of the bound virion. To determine if the ES CD8<sup>+</sup> T cell response to non-productively infected CD4<sup>+</sup> T cells is superior to the response of CP CD8<sup>+</sup> T cells, a variant of the CD8<sup>+</sup> T cell suppression assay was used [21,22,41]. Freshly isolated, unstimulated CD4<sup>+</sup> T cells were infected with 1000 ng of NL4-3 ΔEnv/GFP per 10<sup>6</sup> cells with or without treatment with 10 μM EFV, and co-cultured with either Gag-stimulated or unstimulated CD8<sup>+</sup> T cells at E:T ratios ranging from 1:1 to 1:8. CD8<sup>+</sup> T cell effectors were added to the culture immediately after infection. The percent of cells with intracellular Gag was determined at 6, 18, and 72 hours after infection to measure the kinetics of the CD8<sup>+</sup> T cell response.


The HLA-B\*57 and HLA-B\*5801 alleles are over-represented in ES cohorts [3-9], and HLA-B\*57 is the major genetic determinant of control of HIV-1 replication as identified in multiple genome wide association studies [10-14]. Additionally, HLA-B\*57 is thought to present peptides from structurally conserved regions



of Gag, and mutations in these Gag epitopes have been associated with viral attenuation [42,43]. Therefore, we asked whether CD8<sup>+</sup> T cells from HLA-B\*57/5801<sup>+</sup> ES were able to target proteins from the incoming virion, prior to the productive infection of target CD4<sup>+</sup> T cells. Four experimental groups were analyzed: HLA-B\*57<sup>+</sup>/HLA-B\*5801<sup>+</sup> ES (n=10), HLA-B\*57/5801<sup>+</sup> CP (n=9), HLA-B\*57/5801<sup>-</sup> CP (n=8) and healthy donors (HD) (n=6). Because the HLA-B\*57/5801<sup>+</sup> alleles are thought to present structurally conserved regions in Gag, we analyzed both HLA-B\*57/5801<sup>+</sup> CP and HLA-B\*57/5801<sup>-</sup> CP to determine if there was a difference in the kinetics of the immune response if Gag was specifically targeted.

Figure 2A shows representative FACS plots to illustrate the gating scheme. HIV-1 infection results in Nef-mediated CD4 downregulation [44]; therefore, target CD4<sup>+</sup> T cells were designated as CD3<sup>+</sup>/CD8<sup>-</sup> and then assayed for the expression of Gag (Figure 2A). The percent elimination

was normalized based on the positive control values observed in absence of CD8<sup>+</sup> effector cells. Gag staining can be reliably detected early after spinoculation, and prior to the detection of GFP expression, which requires *de novo* synthesis of proteins encoded on the viral genome. Similar levels of Gag positivity were detected between the ES (49.1% mean Gag positivity) and both CP groups (51.2% and 52.1% mean Gag positivity for B\*57/5801<sup>+</sup> CP and B\*57/5801<sup>-</sup> CP, respectively, data not shown). After 6 hours of co-culture, there were no significant differences between the experimental groups in the levels of elimination at any E:T ratio analyzed (Figure 2B). An increased level of elimination was observed for all experimental groups after 18 hours of infection. The levels of elimination mediated by Gag-peptide stimulated CD8<sup>+</sup> T cells from ES was highest at a 1:1 E:T ratio for both EFV-treated and untreated cells, but did not reach statistical significance between these treatment groups. There was no difference in the level of elimination observed for



**Figure 2** (See legend on next page.)

(See figure on previous page.)


**Figure 2 Elimination of non-productively infected CD4<sup>+</sup> cells.** (A) Representative FACS plots demonstrating the gating scheme employed for the calculation of normalized percent elimination. Cells in culture were stained with anti-CD3 and anti-CD8 antibodies to distinguish targets (CD3<sup>+</sup>/CD8<sup>-</sup>) and effector (CD3<sup>+</sup>/CD8<sup>+</sup>) populations. Target cells were then gated to determine the percent of gag positive cells, as determined by intracellular staining with an anti-Gag antibody. Uninfected target cells were used as a negative control. (B) An elimination assay was performed to determine the ability of CD8 T cells from B\*57/5801<sup>+</sup> ES (n=10; blue squares), B\*57/5801<sup>+</sup>CP (n=9; orange squares), B\*57/5801- CP (n=8; red squares) and healthy donors (HD, n=6; purple squares) to reduce the frequency of Gag positive target cells. Unstimulated CD8<sup>+</sup> T cells or Gag Stimulated CD8<sup>+</sup> T cells were co-cultured with untreated or EFV treated, autologous CD4<sup>+</sup> T cell targets at various effector to target ratios. Elimination was analyzed after 6, 18 and 72 hours post infection. Data points where the level of elimination mediated by the ES CD8 T cells was significantly higher than all other experimental groups are indicated (black asterisks, p<.05). (C) The normalized percent elimination for ES Gag-stimulated and unstimulated effectors, for both untreated and 10 μM EFV treated were analyzed at 72 hours post infection for a 1:1 and 1:8 effector to target ratio. For all treatment groups, no statistical difference in the levels of elimination was observed. Median elimination levels are indicated.

untreated or EFV-treated CD4<sup>+</sup> T cell targets. After 72 hours of infection, there was significantly more elimination by ES CD8<sup>+</sup> T cells compared to CD8<sup>+</sup> T cells from CP or HD. This increased elimination was observed for both unstimulated and Gag-stimulated CD8<sup>+</sup> T cells and was similar when either EFV-treated or untreated CD4<sup>+</sup> targets were used (Figure 2B). Gag peptide stimulation did not dramatically increase the elimination mediated by CD8<sup>+</sup> T cells from either HLA-B\*57/5801<sup>+</sup> CP or HLA-B\*57/5801-CP when compared to unstimulated CD8<sup>+</sup> T cell effectors. This may be due to the fact that CD8<sup>+</sup> T cells from CP undergo limited proliferation [19] and lytic granule loading [3] after stimulation with HIV peptides. No GFP expression was observed for any EFV-treated sample during the first 72 hours after infection (data not shown).


We next asked whether the levels of elimination of non-productively infected cells was less than the elimination of productively infected CD4<sup>+</sup> T cells. Infection of CD4<sup>+</sup> T cells in the presence of 10 μM EFV inhibits viral reverse transcription, and results in non-productively infected cells. For the ES group, the level of elimination of untreated or EFV-treated cells mediated by Gag-stimulated or unstimulated CD8<sup>+</sup> T cells was analyzed 72 hours after infection at a 1:1 E:T ratio and a 1:8 E:T ratio (Figure 1C). No statistically significant difference between the levels of elimination of EFV-treated or untreated CD4<sup>+</sup> T cell targets was observed for either Gag-stimulated or unstimulated CD8<sup>+</sup> T cells.

We confirmed this elimination of non-productively infected CD4<sup>+</sup> T cells by infecting CD4<sup>+</sup> T cells with virus inactivated by treatment with 300 μM aldirithiol-2 (AT-2). This agent has been shown to modify the essential zinc finger domains of HIV-1 nucleocapsid, thus, completely inactivate the virus while maintaining the structure of surface proteins. This allows the virus to enter target cells but does not allow the virus to replicate [45]. We confirmed this by demonstrating the presence of cell-associated Gag protein but not GFP expression after infection (data not shown). ES CD8<sup>+</sup> T cells effectively eliminated CD4<sup>+</sup> T cells infected with AT-2 treated virus, confirming the fact that these CTL can eliminate non-productively infected CD4<sup>+</sup> T cells (Figure 3).

To determine how the amount of input virus affects elimination, we varied the input virus from 1000 ng p24 to 62.5 ng p24 per 10<sup>6</sup> CD4<sup>+</sup> T cells by two fold dilutions. We assayed the normalized percent elimination by unstimulated CD8<sup>+</sup> T cells from 6 ES at a 1:1 E:T ratio after 72 hours after infection. This assay was performed on EFV-treated and untreated CD4<sup>+</sup> T cell targets. Representative FACS plots showing the gating strategy and the percentage of infected cells over the titration range are shown in Figure 4A. There was no statistical difference in



**Figure 3 Elimination of cells infected with inactivated virus.** CD4<sup>+</sup> T cells from two ES (top panels) and two HD (bottom panels) were infected with AT-2 inactivated virus, and the level of Gag positivity was analyzed for target alone wells, and targets with effectors at a 1:1 effector to target ratio. No elimination was mediated by CD8 T cells from HD, in contrast to high level of elimination observed for the two ES assayed.



the level of Gag present in CD4<sup>+</sup> T cell targets with or without EFV treatment. These results confirm that at all the virus input levels tested, the observed Gag-staining does not depend on completion of reverse transcription and likely reflects cell-associated Gag proteins on incoming virus particles bound to or internalized by target cells. The average percent Gag positivity ranged from 65.8 percent to 7.2 percent (Figure 4B, top panel). The normalized percent elimination observed for untreated and EFV-treated CD4<sup>+</sup> targets remained constant over a range of inoculum sizes (Figure 4B, bottom panel). For the untreated cells, the only significant difference in the level of elimination was between the 1000 ng p24 and the 62.5 ng p24 inoculum size (Figure 4B, blue asterisk). In this instance, significantly higher elimination was observed for the lower inoculum


size. For EFV treated targets, there were no statistically significant differences in the level of elimination observed at any viral inoculum size. The level of elimination observed at the 1000, 500, and 250 ng p24 inoculum sizes was not statistically different between the untreated and EFV treated targets. However, there was a significant difference between the elimination observed for the two lowest doses of input virus between the treated and untreated CD4<sup>+</sup> T cell targets (Figure 4B, black asterisks), indicating that recognition of viral infection at lower inoculum sizes might be more dependent on endogenously produced viral proteins. These data indicate that the level of elimination of infected cells is only weakly dependent on the viral inoculum size.

We next asked whether CD8<sup>+</sup> T cells from ES could eliminate both activated and resting target cells. Therefore,

72 hours after infection during analysis, we stained CD4<sup>+</sup> target cells from ES with a cocktail of anti-HLA-DR, anti-CD25, and anti-CD69 antibodies in addition to anti-CD3 and anti-CD8 antibodies used to distinguish targets and effectors. Cells that were positive for one or more of these activation markers were considered to be activated CD4<sup>+</sup> T cells, and those that were negative for all three of these markers were considered to be resting CD4<sup>+</sup> T cells. There were no significant differences in the levels of resting and activated CD4<sup>+</sup> T cells that were productively (GFP<sup>+</sup>) and non-productively (Gag<sup>+</sup> GFP<sup>-</sup>) infected (Additional file 1). The non-productive infection of resting CD4<sup>+</sup> T cells is consistent with a prior study that showed fusion of X4 pseudotyped virus to unstimulated CD4<sup>+</sup> T cells [46]. The GFP expressing resting CD4<sup>+</sup> T cells may represent cells that were recently activated but no longer express classical activation markers. This was not seen in a prior study when resting CD4<sup>+</sup> T cells were purified prior to infection [47], thus it is possible that cytokines secreted by activated CD4<sup>+</sup> T cells in the unfractionated collection of cells may have facilitated the

productive infection of resting CD4<sup>+</sup> T cells. We asked whether CD8<sup>+</sup> T cells from ES could eliminate both of these cell types after 18 and 72 hours after infection, both with and without treatment with EFV. We also calculated the percent elimination of infected cells for unfractionated CD4<sup>+</sup> targets (defined as all CD3<sup>+</sup>/CD8<sup>-</sup> cells within the experimental well). Similar levels of elimination of both resting and activated infected CD4<sup>+</sup> T cells were observed over a range of E:T ratios (Figure 5B). At both 18 and 72 hours after infection, there was no statistical difference between the levels of elimination of activated and resting infected CD4<sup>+</sup> T cells, and no difference when compared to unfractionated CD4<sup>+</sup> T cell targets. Additionally, there was no difference in the level of elimination of infected cells observed when cells were treated or not treated with 10 μM EFV.

Studies have shown that ES CD4<sup>+</sup> T cells have lower levels of total [5,48] and integrated [28] HIV DNA, and replication-competent HIV-1 [29] compared to patients on suppressive HAART regimens. It is possible that precursors of latently infected cells are cells that were



infected as they were transitioning from activated to a resting state, resulting in a non-productively infected cell. Therefore, if ES CD8<sup>+</sup> T were able to effectively target non-productively infected cells through proteins from incoming virions, they would be able to reduce the seeding of the latent reservoir. By treating infected CD4<sup>+</sup> T cells with EFV, and by infecting cells with AT-2 inactivated virus, we were able to produce non-productively infected cells. We were able to demonstrate equal elimination of infected cells between EFV treated and untreated cells and effective elimination of CD4<sup>+</sup> T cells infected with AT-2 inactivated virus. This elimination of infected cells was relatively constant over a wide range of viral inoculum sizes, implying that in some instances, proteins from the infecting virion are sufficient to induce a CD8<sup>+</sup> T cell response without additional viral replication. While levels of virus used in this study may be in excess of levels typically observed in peripheral blood, local concentrations of virus in the tissue and lymph nodes could be similar depending on the HIV-1 burst size as previously hypothesized [38].

While a recent study suggested that HIV-1-specific CD8<sup>+</sup> T cell lines that recognized HLA-B\*57 restricted epitopes were capable of eliminating non-productively CD4<sup>+</sup> T cells [39], we show here that non-stimulated primary CD8<sup>+</sup> T cells from HLA-B\*57/5801 ES were significantly more effective at the elimination of infected CD4<sup>+</sup> T cells than CD8<sup>+</sup> T cells from HLA-B\*57/5801 CP at 72 hours post infection. The reverse transcription process in resting CD4<sup>+</sup> T cells has been shown to take 2–3 days [47], therefore, an increase in the elimination potential over this time frame could limit the seeding of the latent reservoir. Furthermore, non-productively infected CD4<sup>+</sup> T cells would not be expected to die from the cytopathic effect of the virus, so even CTL responses that took 72 hours to mature would be effective at eliminating these cells.

It should be noted that ES are a heterogeneous population, and that not all ES possess previously reported, protective HLA alleles and, in some cases, have weak or absent immune responses [6,7,49,50]. Thus, it would be interesting to determine if ES without protective HLA types are also able to target non-productively infected cells.

While only HLA-B\*57/5801<sup>+</sup> ES were analyzed in this study, these data have implications for the design of an effective HIV-1 vaccine. CD8<sup>+</sup> T cell vaccines that are able to elicit a potent response early in infection may have the potential to reduce the seeding of the latent reservoir. The CD8<sup>+</sup> T cell responses described may partially explain the low frequency of latently infected cells that is observed in ES. The small reservoir size may be due to both the effective elimination of productively infected CD4<sup>+</sup> T cells [3,16,18–22], which would limit the level of viremia and the subsequent seeding of the

reservoir, and by the elimination of non-productively infected CD4<sup>+</sup> T cells that may be the precursors of the latent reservoir. These data could also explain why ES maintain low frequencies of latently infected cells in chronic infection in spite of ongoing HIV-1 replication [51–55]; recently infected resting and activated CD4<sup>+</sup> T cells will be eliminated regardless of whether productive or non-productive infection occurs.

## Conclusions

This is the first study to show effective elimination of non-productively infected CD4<sup>+</sup> T cells by unstimulated primary HIV-1-specific CD8<sup>+</sup> T cells from ES. The results suggest that an early and potent CD8<sup>+</sup> T cell immune response could result in a lower baseline latent reservoir size as has been seen with a potent CD8<sup>+</sup> T cell vaccine in the SIV model [35]. Latency remains the largest barrier to the eradication of HIV-1 infection, and understanding the mechanisms of an optimal CD8<sup>+</sup> T cell response can allow for improved immune based eradication strategies.

## Methods

### Patients

All individuals provided written informed consent prior to participating in this study, and all studies were approved by the Johns Hopkins Institutional Review Board. All ES maintained undetectable plasma HIV-1 RNA levels for the duration of study (<50 copies/mL) and are positive for the HLA-B\*57/5801 allele. The median CD4<sup>+</sup> T cell count for the ES used in this study was 857 cells/ul (range 453–1638 cells/ul), and the median duration of infection was 13 years (range 4–28 years). All CP were on suppressive antiretroviral therapy for greater than a year at the time of study. Of the CP used for the study, 9 were positive for the HLA-B\*57/5801 allele and 8 were negative for the HLA-B\*57/5801 allele. Seronegative controls were 6 healthy laboratory workers (HD, healthy donors).

### Isolation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells

PBMCs were isolated from whole blood by ficoll gradient centrifugation. CD8<sup>+</sup> T cells were isolated by positive selection using Human CD8 Microbeads following the manufacturer's guidelines (Miltenyi Biotec). CD4<sup>+</sup> T cell were subsequently isolated by negative selection using the Human CD4 T cell isolation kit II following the manufacturer's guidelines (Miltenyi Biotec). All cells were maintained in non-stimulating media (RPMI + 10% FBS without exogenous cytokines) for the duration of experimentation unless otherwise noted.

### Infection

An NL4-3 pseudovirus with GFP in the place of Env (NL4-3 ΔEnv/GFP) was used for all infections, as previously described [56]. The virus was produced by cotransfection



of 239 T cells with the proviral construct pNL4-3  $\Delta$ Env/GFP and either an R5 or X4 Env expression vector to provide the Env in trans. The *env* expression vectors have been routinely used by our lab group [57]. CD4<sup>+</sup> T cells were infected by spinoculation as previously described [58]. Briefly, CD4<sup>+</sup> T cells were isolated and collected in 50 mL conical tubes. The cells were pelleted by centrifugation at 1200 RPM for 10 minutes, and all supernatant was removed. The cells were then resuspended in the viral inoculum. Spinoculation was performed by spinning at 1200  $\times$  g for 2 hours at room temperature. Cells were then resuspended at a concentration of  $1 \times 10^6$  cells/mL and plated at  $1 \times 10^5$  cells/well in a 96 well, round bottom plate. CD4<sup>+</sup> T cells were not activated prior to spinoculation. Rather they were isolated directly from donors and maintained in non-stimulating media for the duration of the experiment as previously described [57,59]. CD4<sup>+</sup> T cells were infected with a viral inoculum that routinely resulted in approximately 15-20% infection after 72 hours post infection, as measured by GFP expression (1000 ng p24/1e6 cells). For titration experiments, the level of virus was titrated by two fold dilutions from 1000 ng p24/10<sup>6</sup> cells to 62.5 ng p24/10<sup>6</sup> cells.

For experiments involving efavirenz (EFV) treatment, EFV was added to CD4<sup>+</sup> T cells at the time of spinoculation and maintained in the culture for the duration of the experiment at 10  $\mu$ M which is greater than the IC<sub>99</sub>. Treatment of CD4<sup>+</sup> T cells with EFV prevented any expression of GFP after 72 hours of infection in any of the treated wells (data not shown). An aliquot of uninfected CD4<sup>+</sup> T cells was kept as a negative control.

For experiments involving maraviroc (MVC), ADM3100 (ADM) and T20, drug was added to CD4<sup>+</sup> T cells at the time of spinoculation and maintained in the culture for the duration of the experiment at 10  $\mu$ M, 10  $\mu$ M and 25 nM, respectively, which is greater than the IC<sub>99</sub>.

AT-2 inactivated virus was produced as previously described [45]. Briefly, NL4-3  $\Delta$ Env/GFP virus was treated with 300  $\mu$ M AT-2 (Sigma) for 1 hour at 37°C. After incubation, virus was filtered using Amicon Ultra 0.5 mL filtration tubes (Millipore). Virus was then kept on ice until use in the CD8<sup>+</sup> suppression assay.

#### CD8<sup>+</sup> T Cell elimination of infected cells assay

The CD8<sup>+</sup> T cell elimination assay was modified from a previously reported suppression assay [21,22]. We measured the reduction in the number of cells expressing Gag in the presence of CD8<sup>+</sup> T cells. Because we used a single cycle virus, this reduction was most likely due to killing of infected cells although we do not directly prove this in this study. To prepare Gag-stimulated CD8<sup>+</sup> T cells, PBMCs from patients or HD were isolated one week prior to the execution of the suppression assay (day -7). PBMCs were stimulated with a mixture of

overlapping Gag peptides that spanned the length of Gag at a total concentration of 5  $\mu$ g/mL and IL-2 (2 units/mL). After one week, Gag-stimulated, CD8<sup>+</sup> effectors were isolated by positive selection using CD8 microbeads (Miltenyi Biotech). A second blood draw was obtained from each patient or HD on the same day, and unstimulated CD8<sup>+</sup> T cell effectors and autologous CD4<sup>+</sup> T cell targets were isolated directed *ex vivo*, by positive and negative selection, respectively. CD8<sup>+</sup> T cells were added to infected CD4<sup>+</sup> T cell targets immediately after spinoculation. The infected CD4<sup>+</sup> targets, with or without EFV treatment, and either Gag-stimulated or unstimulated CD8 effectors were co-cultured in a 96 well plate at varying effector to target (E:T) ratios. The number of CD4<sup>+</sup> T cells per well remained constant (100,000 cells per well), and the number of CD8<sup>+</sup> T cells was varied. The cells were cultured in a final volume of 200  $\mu$ L of non-stimulating media. CD8<sup>+</sup> T cells were serially diluted from a 1:1 effector to target (E:T) ratio to a 1:8 E:T ratio by two-fold dilutions. Wells with only CD4<sup>+</sup> T cells (targets alone) were used as positive controls for normalization.

Elimination of infected cells was measured at 6, 18 and 72 hours after infection to determine the kinetics of the response. To measure infection, cells were stained with anti-CD3 Pac Blue (Becton Dickinson), anti-CD8 APC-H7 (Becton Dickinson), and anti-Gag PE (Beckman Coulter, coulter clone kc57). For intracellular staining, the Cytofix/Cytoperm was solution was used following the manufacturers guidelines (Becton Dickinson). The normalized percent elimination of infected cells was calculated as follows: (Percent Gag<sup>+</sup> cells in wells with Targets alone – Percent of CD4<sup>+</sup> T cells that are Gag<sup>+</sup> in wells with Targets and Effectors) / (Percent Gag<sup>+</sup> cells in wells with Targets alone)  $\times$  100, as described previously [41].

For the titration experiments, CD4<sup>+</sup> T cells were infected with various viral inoculums, and cultured with or without unstimulated CD8<sup>+</sup> T cells at a 1:1 E:T ratios. Cultures without CD8<sup>+</sup> effectors served as the positive control for normalization.

For a subset of ES, cells were also stained with a cocktail of anti-HLA-DR APC, anti-CD25 APC, and anti-CD69 APC (Becton Dickinson). CD4<sup>+</sup> T cell targets that expressed any one of these markers were designated activated CD4<sup>+</sup> T cells, those that were negative for all three markers were designated as resting CD4<sup>+</sup> T cells, as gated using the FACS Diva software. The percent infection of unfractionated CD4<sup>+</sup> T cells (all CD3<sup>+</sup>/CD8<sup>-</sup> cells), resting CD4<sup>+</sup> T cells and activated CD4<sup>+</sup> T cells was calculated, and the normalized percent elimination of infected cells of each subset was calculated.

All cytometric analyses were performed using a FACS Canto II (Becton Dickinson) and analyzed using the FACS Diva software.

### Statistical analysis

For the analysis of the significance of the difference between populations, the Mann–Whitney nonparametric T test was used. For pair-wise comparison of untreated vs. EFV-treated cells, a paired Student's T test was used. P values were calculated, and a P value of less than 0.05 was considered significant.

### Additional file

**Additional file 1: Percent of Gag and GFP positive resting and activated cells present at 18 and 72 hours post infection in the presence or absence of EFV.**

### Competing interests

The authors declare no competing financial conflicts of interest.

### Authors' contributions

RWB carried out all experiments, and drafted the manuscript. RFS participated in the design and planning of experiments and helped to edit the manuscript. JNB conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

This work was supported by NIH grant R01 AI080328 (J.N.B.) and the Howard Hughes Medical Institute (R.F.S.).

### Author details

<sup>1</sup>Department of Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, BRB 880, Baltimore, MD 21205, USA. <sup>2</sup>Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.

Received: 10 May 2013 Accepted: 27 June 2013

Published: 1 July 2013

### References

- Blankson JN: **The study of elite controllers: a pure academic exercise or a potential pathway to an HIV-1 vaccine?** *Curr Opin HIV AIDS* 2011, **6**(3):147–150.
- Ockulicz J, Lambotte O: **1. Epidemiology and clinical characteristics of elite controllers.** *Current Opinions on HIV AIDS* 2011, **6**(3):163–168.
- Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP, Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA, Connors M: **Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.** *Immunity* 2008, **29**(6):1009–1021.
- Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M: **HLA B\*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.** *Proc Natl Acad Sci USA* 2000, **97**(6):2709–2714.
- Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, Rouzioux C, Venet A, Delfraissy JF, SEROCO-HEMOCO Study Group: **HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.** *Clin Infect Dis* 2005, **41**(7):1053–1056.
- Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG: **HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.** *J Virol* 2008, **82**(11):5398–5407.
- Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD: **Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.** *J Infect Dis* 2008, **197**(4):563–571.
- Han Y, Lai J, Barditch-Crovo P, Gallant JE, Williams TM, Siliciano RF, Blankson JN: **The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors.** *AIDS* 2008, **22**(4):541–544.
- Sajadi MM, Constantine NT, Mann DL, Charurat M, Dadzan E, Kadlecik P, Redfield RR: **Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors.** *J Acquir Immune Defic Syndr* 2009, **50**(4):403–408.
- Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB: **A whole-genome association study of major determinants for host control of HIV-1.** *Science* 2007, **317**(5840):944–947.
- International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burt NP, Guiducci C, Gupta N, Gao X, et al: **The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.** *Science* 2010, **330**(6010):1551–1557.
- Catano G, Kulkarni H, He W, Marconi VC, Agan BK, Landrum M, Anderson S, Delmar J, Telles V, Song L, Castiblanco J, Clark RA, Dolan MJ, Ahuja SK: **HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B\*57 alleles.** *PLoS One* 2008, **3**(11):e3636.
- Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, Lambotte O, Avettand-Fenoel V, Le Clerc S, de Senneville LD, Deveau C, Boufassa F, Debre P, Delfraissy JF, Broet P, Theodorou I, ANRS Genome Wide Association 01: **Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.** *PLoS One* 2008, **3**(12):e3907.
- Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, Labib T, Taing L, Sladek R, Deveau C, Ratsimandresy R, Montes M, Spadoni JL, Lelievre JD, Levy Y, Therwath A, Schachter F, Matsuda F, Gut I, Froguel P, Delfraissy JF, Hercberg S, Zagury JF, ANRS Genomic Group: **Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02).** *J Infect Dis* 2009, **199**(3):419–426.
- van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, van't Wout AB, Schuitemaker H: **Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection.** *AIDS* 2009, **23**(1):19–28.
- Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA: **HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.** *Blood* 2006, **107**(12):4781–4789.
- Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V: **Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.** *J Exp Med* 2007, **204**(10):2473–2485.
- Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB, Yee HF Jr, Martin JN, Deeks SG, Shacklett BL: **Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control.** *Blood* 2009, **113**(17):3978–3989.
- Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, Connors M: **HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.** *Nat Immunol* 2002, **3**(11):1061–1068.
- Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, Kovacs CM, Rodriguez B, Sieg SF, Teixeira-Johnson L, Gudonis D, Goepfert PA, Lederman MM, Frank I, Makedonas G, Kaul R, Walker BD, Betts MR: **Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control.** *PLoS Pathog* 2010, **6**(5):e1000917.
- Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fenoel V, Rouzioux C, Delfraissy JF, Barre-Sinoussi F, Lambotte O, Venet A, Pancino G, ANRS EP36 HIV Controllers Study Group: **Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses.** *J Immunol* 2009, **182**(12):7828–7837.

22. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barre-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A, Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group: **HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.** *Proc Natl Acad Sci USA* 2007, **104**(16):6776–6781.
23. Friedrich TC, Valentine LE, Yant LJ, Rakasz EG, Piaskowski SM, Furlott JR, Weisgrau KL, Burwitz B, May GE, Leon EJ, Soma T, Napoe G, Capuano SV 3rd, Wilson NA, Watkins DI: **Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication.** *J Virol* 2007, **81**(7):3465–3476.
24. Pandrea I, Gauffin T, Gautam R, Kristoff J, Mandell D, Montefiori D, Keele BF, Ribeiro RM, Veazey RS, Apetrei C: **Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion.** *PLoS Pathog* 2011, **7**(8):e1002170.
25. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, Baker B, Rosenberg R, Cutrell E, Seaman MS, Coffin JM, Walker BD: **Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.** *J Infect Dis* 2009, **200**(6):984–990.
26. Dinoso JB, Kim SY, Siliciano RF, Blankson JN: **A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.** *Clin Infect Dis* 2008, **47**(1):102–104.
27. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG: **Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.** *J Virol* 2009, **83**(1):329–335.
28. Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di Mascio M, Migueles SA, Connors M, O'Doherty U: **Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.** *PLoS Pathog* 2011, **7**(2):e1001300.
29. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF: **Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.** *J Virol* 2007, **81**(5):2508–2518.
30. Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, Martinez-Picado J, Addo MM, Walker BD: **Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.** *Clin Infect Dis* 2010, **51**(2):233–238.
31. Siliciano JD, Siliciano RF: **Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals.** *Methods Mol Biol* 2005, **304**:3–15.
32. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJ, Walker BD: **Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.** *AIDS* 2003, **17**(18):2581–2591.
33. Goujard C, Chaix ML, Lambotte O, Deveau C, Sinet M, Guernon J, Courgnaud V, Rouzioux C, Delfraissy JF, Venet A, Meyer L, Agence Nationale de Recherche sur le Sida PRIMO Study Group: **Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?** *Clin Infect Dis* 2009, **49**(6):982–986.
34. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF: **Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation.** *Immunity* 2012, **36**(3):491–501.
35. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M Jr, Lifson JD, Picker LJ: **Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.** *Nature* 2011, **473**(7348):523–527.
36. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, Zhou Y, Shrum CK, Han Y, Liu JO, Zhang H, Margolick JB, Siliciano RF: **Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.** *J Clin Invest* 2009, **119**(11):3473–3486.
37. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, Bushman FD, O'Doherty U: **Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency.** *PLoS Pathog* 2012, **8**(7):e100218.
38. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, Bean AT, Lee W, Burwitz BJ, Stephany JJ, Loffredo JT, Allison DB, Adnan S, Hoji A, Wilson NA, Friedrich TC, Lifson JD, Yang OO, Watkins DI: **Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression.** *J Immunol* 2007, **178**(5):2746–2754.
39. Kloverpris HN, Payne RP, Sacha JB, Rasaiyaah JT, Chen F, Takiguchi M, Yang OO, Towers GJ, Goulder P, Prado JG: **Early Antigen Presentation of Protective HIV-1 KF11Gag and KK10Gag Epitopes from Incoming Viral Particles Facilitates Rapid Recognition of Infected Cells by Specific CD8+ T Cells.** *J Virol* 2013, **87**(5):2628–2638.
40. Buseyne F, Le Gall S, Boccaccio C, Abastado JP, Lifson JD, Arthur LO, Riviere Y, Heard JM, Schwartz O: **MHC-I-restricted presentation of HIV-1 virion antigens without viral replication.** *Nat Med* 2001, **7**(3):344–349.
41. Buckheit RW 3rd, Salgado M, Siliciano RF, Blankson JN: **Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors.** *J Virol* 2012, **86**(24):13679–13688.
42. Martinez-Picado J, Prado JG, Fry EE, Pfafferoth K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P: **Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.** *J Virol* 2006, **80**(7):3617–3623.
43. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, Ryykin F, Derdeyn CA, Allen S, Hunter E, Mulenga J, Goepfert PA, Walker BD, Allen TM: **Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A.** *J Virol* 2007, **81**(22):12608–12618.
44. Garcia JV, Miller AD: **Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.** *Nature* 1991, **350**(6318):508–511.
45. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, Vasquez GM, Wiltout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD: **Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.** *J Virol* 1998, **72**(10):7992–8001.
46. Agosto LM, Yu JJ, Liszewski MK, Baytop C, Korokhov N, Humeau LM, O'Doherty U: **The CXCR4-tropic human immunodeficiency virus envelope promotes more-efficient gene delivery to resting CD4+ T cells than the vesicular stomatitis virus glycoprotein G envelope.** *J Virol* 2009, **83**(16):8153–8162.
47. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, Siliciano RF: **Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.** *J Virol* 2002, **76**(17):8518–8531.
48. Spivak AM, Salgado M, Rabi SA, O'Connell KA, Blankson JN: **Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.** *J Virol* 2011, **85**(19):10399–10403.
49. Yang H, Wu H, Hancock G, Clutton G, Sande N, Xu X, Yan H, Huang X, Angus B, Kuldanek K, Fidler S, Denny TN, Birks J, McMichael A, Dorrell L: **Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection.** *J Infect Dis* 2012, **206**(4):552–561.
50. Mendoza D, Johnson SA, Peterson BA, Natarajan V, Salgado M, Dewar RL, Burbelo PD, Doria-Rose NA, Graf EH, Greenwald JH, Hodge JN, Thompson WL, Cogliano NA, Chairez CL, Rehm CA, Jones S, Hallahan CW, Kovacs JA, Sereti I, Sued O, Peel SA, O'Connell RJ, O'Doherty U, Chun T, Connors M, Migueles SA: **Comprehensive analysis of unique cases with extraordinary control over HIV replication.** *Blood* 2012, **119**(20):4645–4655.
51. Bailey JR, Brennan TP, O'Connell KA, Siliciano RF, Blankson JN: **Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B\*57+ elite suppressors.** *J Virol* 2009, **83**(1):88–97.
52. Bailey JR, Williams TM, Siliciano RF, Blankson JN: **Maintenance of viral suppression in HIV-1-infected HLA-B\*57+ elite suppressors despite CTL escape mutations.** *J Exp Med* 2006, **203**(5):1357–1369.
53. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN: **Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.** *J Virol* 2010, **84**(14):7018–7028.
54. Salgado M, Brennan TP, O'Connell KA, Bailey JR, Ray SC, Siliciano RF, Blankson JN: **Evolution of the HIV-1 nef gene in HLA-B\*57 positive elite suppressors.** *Retrovirology* 2010, **7**:94.
55. Mens H, Kearney M, Wiegand A, Shao W, Schonning K, Gerstoft J, Obel N, Maldarelli F, Mellors JW, Benfield T, Coffin JM: **HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.** *J Virol* 2010, **84**(24):12971–12981.

56. Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, Li Q, Pham P, Cofrancesco J, Persaud D, Siliciano RF: **Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.** *J Virol* 2004, **78**(4):1718–1729.
57. O'Connell KA, Rabi SA, Siliciano RF, Blankson JN: **CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors.** *Proc Natl Acad Sci USA* 2011, **108**(37):E689–98.
58. O'Doherty U, Swiggard WJ, Malim MH: **Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.** *J Virol* 2000, **74**(21):10074–10080.
59. Rabi SA, O'Connell KA, Nikolaeva D, Bailey JR, Jilek BL, Shen L, Page KR, Siliciano RF, Blankson JN: **Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection.** *J Virol* 2011, **85**(2):979–986.

doi:10.1186/1742-4690-10-68

**Cite this article as:** Buckheit *et al.*: Primary CD8<sup>+</sup> T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4<sup>+</sup> T cells. *Retrovirology* 2013 **10**:68.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

 **BioMed** Central